Aloxiprin

Aloxiprin
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	B01AC15 (WHO) N02BA02 (WHO);
Legal status
Legal status	AU: S2 (Pharmacy medicine);
Identifiers
	IUPAC name aluminium 2-acetyloxybenzoate hydroxide;
CAS Number	9014-67-9;
PubChem CID	71586929;
ChemSpider	32698107;
UNII	6QT214X4XU;
KEGG	D07421;
CompTox Dashboard (EPA)	DTXSID60238044 ;
Chemical and physical data
Formula	C9H8Al2O7
Molar mass	282.119 g·mol−1
3D model (JSmol)	Interactive image; Interactive image;
	SMILES CC(=O)OC1=CC=CC=C1C(=O)O.[O-2].[O-2].[O-2].[Al+3].[Al+3]; ; CC(=O)Oc0ccccc0C(=O)O[Al](O)OC(=O)c1ccccc1OC(=O)C;
	InChI InChI=1S/C9H8O4.2Al.3O/c1-6(10)13-8-5-3-2-4-7(8)9(11)12;;;;;/h2-5H,1H3,(H,11,12);;;;;/q;2+3;3-2; Key:MXCPYJZDGPQDRA-UHFFFAOYSA-N;

Aloxiprin (or aluminium acetylsalicylate) is a medication used for the treatment of pain and inflammation associated with muscular skeletal and joint disorders. It is used for its properties as an anti-inflammatory, antipyretic and analgesic drug.^[2] It is a chemical compound of aluminium hydroxide and aspirin.^[3]^[4]

Alternative names and combinations

Palaprin Forte^[5]
Askit Powders - A powder combination of aspirin, aloxiprin and caffeine.^[6]

Contraindications

People with allergies to salicylates.
People with gastrointestinal ulcers.
People with liver or kidney damage.
Pregnant women in the third trimester.
Women who are breastfeeding.
Use with other salicylates.
Use with Nonsteroidal anti-inflammatory drugs (NSAIDs).

References

↑ "Therapeutic Goods (Poisons Standard— June 2025) Instrument 2025" (pdf). Therapeutic Goods Administration (TGA). May 2025. Retrieved 31 August 2025.
↑ MIMS. "Aloxiprin". MIMS. Retrieved 16 April 2011.
↑ Encarta. "Aloxiprin". Encarta. Retrieved 16 April 2011.
↑ CUMMINGS AJ, MARTIN BK, WIGGINS LF (1963). "In vitro and in vivo properties of aloxiprin: a new aluminium derivative of acetylsalicylic acid". J. Pharm. Pharmacol. 15: 56–62. doi:10.1111/j.2042-7158.1963.tb12743.x. PMID 14024235. S2CID 33366977.
↑ Geller J (1968). "A comparative trial of aloxiprin ('Palaprin Forte') and phenylbutazone ('Butazolidin')". The British Journal of Clinical Practice. 22 (9): 392–4. PMID 4876729.
↑ Net Doctor UK. "Askit Powders". Treatments for joint, muscle and bone conditions. Retrieved 16 April 2011.

[1] "Therapeutic Goods (Poisons Standard— June 2025) Instrument 2025" (pdf). Therapeutic Goods Administration (TGA). May 2025. Retrieved 31 August 2025.

[mimsonline-2] MIMS. "Aloxiprin". MIMS. Retrieved 16 April 2011.

[3] Encarta. "Aloxiprin". Encarta. Retrieved 16 April 2011.

[pmid14024235-4] CUMMINGS AJ, MARTIN BK, WIGGINS LF (1963). "In vitro and in vivo properties of aloxiprin: a new aluminium derivative of acetylsalicylic acid". J. Pharm. Pharmacol. 15: 56–62. doi:10.1111/j.2042-7158.1963.tb12743.x. PMID 14024235. S2CID 33366977.

[pmid4876729-5] Geller J (1968). "A comparative trial of aloxiprin ('Palaprin Forte') and phenylbutazone ('Butazolidin')". The British Journal of Clinical Practice. 22 (9): 392–4. PMID 4876729.

[6] Net Doctor UK. "Askit Powders". Treatments for joint, muscle and bone conditions. Retrieved 16 April 2011.

[1]

[2]

[3]

[4]

[5]

[6]

Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)
pyrazolones / pyrazolidines	Aminophenazone Ampyrone Azapropazone Clofezone Difenamizole Famprofazone Feprazone Kebuzone Metamizole Mofebutazone Morazone Nifenazone Oxyphenbutazone Phenazone Phenylbutazone Propyphenazone Sulfinpyrazone Suxibuzone^‡
salicylates	Aspirin (acetylsalicylic acid)^# Aloxiprin Benorylate Carbasalate calcium Diflunisal Dipyrocetyl Ethenzamide Guacetisal Magnesium salicylate Methyl salicylate Salsalate Salicin Salicylamide Salicylic acid (salicylate) Sodium salicylate
acetic acid derivatives and related substances	Aceclofenac Acemetacin Alclofenac Amfenac Bendazac Bromfenac Bufexamac Bumadizone Diclofenac Difenpiramide Etodolac Felbinac Fenclozic acid Fentiazac Indometacin Indometacin farnesil Isoxepac Ketorolac Lonazolac Mofezolac Oxametacin Prodolic acid Proglumetacin Sulindac Tiopinac Tolmetin Zomepirac^†
oxicams	Ampiroxicam Droxicam Isoxicam Lornoxicam Meloxicam Piroxicam Pivoxicam Tenoxicam
propionic acid derivatives (profens)	Alminoprofen Benoxaprofen^† Carprofen^‡ Dexibuprofen Dexketoprofen Fenbufen Fenoprofen Flunoxaprofen Flurbiprofen Ibuprofen^# Ibuproxam Indoprofen^† Ketoprofen Loxoprofen Miroprofen Naproxen Oxaprozin Pelubiprofen Piketoprofen Pirprofen Suprofen Tarenflurbil Tepoxalin^‡ Tiaprofenic acid Vedaprofen^‡ Zaltoprofen COX-inhibiting nitric oxide donator: Naproxcinod
n-arylanthranilic acids (fenamates)	Azapropazone Clonixin Etofenamate Floctafenine Flufenamic acid Flunixin Flutiazin Glafenine^† Meclofenamic acid Mefenamic acid Morniflumate Niflumic acid Tolfenamic acid
COX-2 inhibitors (coxibs)	Apricoxib Celecoxib (+tramadol) Cimicoxib^‡ Deracoxib^‡ Etoricoxib Firocoxib^‡ Lumiracoxib^† Mavacoxib^‡ Parecoxib Robenacoxib^‡ Rofecoxib^† Valdecoxib^†
other	Aminopropionitrile Benzydamine Chondroitin sulfate Diacerein Fluproquazone Glucosamine Glycosaminoglycan Grapiprant^‡ Hyperforin Nabumetone Nimesulide Oxaceprol Proquazone Superoxide dismutase / orgotein Tenidap
NSAID combinations	Ibuprofen/famotidine Ibuprofen/hydrocodone Ibuprofen/oxycodone Ibuprofen/paracetamol Meloxicam/bupivacaine Meloxicam/rizatriptan Naproxen/diphenhydramine Naproxen/esomeprazole
Key: underline indicates initially developed first-in-class compound of specific group; ^#WHO-Essential Medicines; ^†withdrawn drugs; ^‡veterinary use.
category commons portal